Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Nippon Shinyaku
Nippon Shinyaku
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Viltepso
Viltolarsen
2020-08-12
2031
Duchenne muscular dystrophy
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Viltolarsen
duchenne muscular dystrophy
,
muscular dystrophies
Aglatimagene besadenovec
leiomyoma
,
myofibroma
,
head and neck neoplasms
,
esophageal neoplasms
,
disease progression
,
neuroendocrine carcinoma
,
castration-resistant prostatic neoplasms
,
adenocarcinoma
,
carcinoma
,
large b-cell lymphoma diffuse
,
urogenital neoplasms
,
male genital neoplasms
,
lymphoma
,
small cell lung carcinoma
,
renal cell carcinoma
,
male genital diseases
,
prostatic diseases
,
abdominal neoplasms
,
genital diseases
,
leukemia
,
myelomonocytic leukemia chronic
,
systemic mastocytosis
,
myelomonocytic leukemia juvenile
,
hypereosinophilic syndrome
,
mastocytosis
,
dermatofibrosarcoma
,
hematologic neoplasms
,
sarcoma
,
b-cell lymphoma
,
neuroendocrine tumors
,
renal insufficiency
,
urologic neoplasms
,
kidney neoplasms
,
endometrial neoplasms
,
t-cell lymphoma
,
malignant mesothelioma
,
clear cell adenocarcinoma
,
mesothelioma
,
adenomyoepithelioma
,
anemia
,
thrombocytopenia
,
pancytopenia
,
cytopenia
,
x-linked bulbo-spinal atrophy
,
neoplasms
,
osteoporosis
,
lung neoplasms
,
pain
,
recurrence
,
bone resorption
,
hypercalcemia
,
prostatic neoplasms
,
neoplasm metastasis
,
breast neoplasms
,
bone neoplasms
,
bone marrow diseases
,
multiple myeloma
,
second primary neoplasms
,
plasma cell neoplasms
,
hypersensitivity
,
plasmacytoma
,
osteonecrosis
Alfacalcidol
hiv infections
,
acquired immunodeficiency syndrome
,
chronic hepatitis c
,
drug-related side effects and adverse reactions
,
melanoma
ILGINATINIB
essential thrombocythemia
,
polycythemia vera
,
primary myelofibrosis
,
thrombocytosis
,
polycythemia
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use